Loading...
Home2018-10-24T19:56:59+00:00

A closer look at biotechnology matters and their legal implications.

The latest issues in the world of advanced medicine, pharmacology, cosmetics, personal care products, and artificial intelligence.

Shook Shorts:
The Art of Courtroom Science

“The cases that we try are high-exposure cases; a lot of money is at stake by any measure. They are dangerous cases. That’s the only way to describe them. If the facts were so perfect and terrific and great for us there probably wouldn’t be a trial in the first place.”

Hildy Sastre

READ THE TRANSCRIPT

recent results

Shook’s Stryker team has won a significant defense verdict in Florida state court after a four-week trial related to the design of a surgical suction device that was recalled by the U.S. Food and Drug Administration (FDA).

READ MORE

The Sixth Circuit has affirmed the dismissal of a putative class action lawsuit against Pfizer and Bristol-Myers Squibb alleging violations of the Telephone Consumer Protection Act (TCPA), ruling that the companies have no liability for faxes sent by a third party without their knowledge, even though the faxes contained advertisements for their products. Shook Partner Becky Schwartz represented Pfizer in the district court win, and successfully defended it on appeal with Of Counsel Molly Carella.

READ MORE

The U.S. Supreme Court has denied a petition for writ of certiorari filed by plaintiffs in the Mirena® multidistrict litigation, effectively ending litigation in federal courts that involved more than 1,300 plaintiffs and lasted more than five years.

READ MORE

A Shook team has obtained their third win in a year for Pharmacia & Upjohn Co. LLC (Pharmacia), the maker of the corticosteroid drug Depo-Medrol® (methylprednisone acetate). Partners Jennise StubbsPaul La Scalaand Associate Sonila Themeli represent Pharmacia.

READ HERE

Shook teams have obtained back-to-back wins for Medtronic, manufacturer of surgical and medical devices, persuading federal courts in Michigan and Texas to dismiss product liability claims against the company.

READ MORE

The United States Court of Appeals for the Eleventh Circuit has affirmed a lower court’s grant of summary judgment in favor of the makers and marketers of the biologic drug Enbrel, finding that the plaintiffs’ injury claims were barred by the learned intermediary doctrine and that the direct “patient labeling requirement” in the U.S. Food and Drug Administration (FDA) medication guidelines did not preempt application of the doctrine. Shook Partner Dan Rogers, with co-counsel Hogan Lovells, represented pharmaceutical companies Amgen, Pfizer and Wyeth on appeal; Partner Bill Geraghty and Associate Iain Kennedy, with co-counsel Hogan Lovells, represented defendants in the district court.

READ MORE

 Past outcomes afford no guarantee of future results. Every case is different and must be judged on its own merits.








“I try to understand both the regulatory and business challenges that my clients’ businesses face on a daily basis. I feel that truly understanding these challenges allows me to provide assistance that will benefit my client both from a short-term and long-term perspective.”

Sonali Gunawardhana

FULL INTERVIEW



2018

Artificial Intelligence

SPECIAL LEGAL REPORT


READ THE REPORT

contact

Madeleine M. McDonough
Madeleine M. McDonough
Alicia J. Donahue
Alicia J. Donahue
LIFE SCIENCES AT SHOOK